Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of mal
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.